



Product Information

Product ID S336505

CAS No. 1224591-33-6

Chemical Name 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one

Synonym PTI-125; PTI-910; C0105; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-


Formula C₁₅H₂₁N₃O

Formula Wt. 259.35

Melting Point

Purity

Solubility



Bulk quantities available upon request

Product ID	Size
S336505	1 mg
S336505	5 mg
S336505	25 mg

Store Temp -20° C

Ship Temp Ambient

Description Simufilam was first introduced as having the potential to reduce biomarkers of Alzheimer's disease. The original data has since become suspect and could not be found. Fraud charges have been filed by the SEC. Simufilam may or may not have some useful bioactivities. The proper research, with proper data collection and analysis, is still to be done.

References Pillar C. Research backing experimental Alzheimer's drug was first target of suspicion. Science. 2022 Jul 22;377(6604):363. PMID: 35862516

Pillar C. Probe of Alzheimer's studies finds 'egregious misconduct'. Science. 2023 Oct 20;382(6668):251-252. PMID: 37856608

Dyer O. Scientist who worked on Cassava's Alzheimer drug simufilam charged with fraud. BMJ. 2024 Jul 15; 386:q1568. PMID: 39009358

Frontiers Editorial Office. Expression of concern: simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer's disease patient lymphocytes. Front Aging. 2024 Aug 22;5:1483030. PMID: 39239266

Pillar C. Firm misled investors on Alzheimer's drug, SEC charges. Science. 2024 Oct 4;386(6717):15. PMID: 39361735

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.